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Abstract
Background: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled trials (RCT) of new
treatments for relapsing remitting multiple sclerosis (RRMS) have decreased substantially during the last two decades. The
causes of these changes are not clear. We consider a better understanding of this phenomenon essential for valuing the
effects of new drugs and by designing new trials.
Objectives: To identify predictive factors of on-study ARR in early and recent MS trials.
Methods: ARR, rate of relapse-free patients, trial start dates, baseline demographics, relapse definitions and the use of
McDonald criteria were retrieved by literature research of the placebo cohorts from RRMS phase-3 trials. Predictors were
estimated by univariate and multivariate regression analyses and random-effects meta-regression. In addition, regression
models were calculated by the Sylvia Lawry Centre’s (SLC), including individual case data from clinical trials performed until
2000. The most reliable meta-analytic results can be gained from pooled individual case data. In lack of this, random-effects
meta-analyses are recommended.
Results: Data from 12 published and one unpublished trial show a decrease of ARR from 1988 to 2012 (adjR2 = 0.807,
p,0.0001). Regression models identified McDonald criteria followed by baseline mean age and the pre-study relapse rate as
predictors of the ARR. The pooled individual case data (n = 505) confirmed a decrease of ARR over time. The pre-study
relapse rate was the best predictor for on-study relapses. Lacking individual case data after implementation of the
McDonald criteria excludes a direct comparison concerning McDonald criteria.
Conclusion: Pre-study relapse rate was the best predictor for on-study relapse rate but failed to explain the decrease of the
ARR over time alone. Higher age at baseline and the implementation of McDonald criteria were associated as well with a
lowered relapse rate in the random-effects meta-regression. These findings need further clarification based on individual
case data.
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Introduction
Relapses have been used widely as primary outcome in clinical
phase-3 trials in relapsing-remitting Multiple Sclerosis (RRMS).
Their future role in MS trial design is under discussion as
annualized relapse rates (ARR) in the placebo cohorts of the 2010
published Fingolimod and Cladribine trials (ARR=0.4 respec-
tively 0.33) were substantially lower than in comparable trials of
the 1990 s (e.g Interferon-ß-1a i.m. ARR=0.9 and s.c.
ARR=1.28). [1–4] This observation leads to a major design
problem for upcoming RRMS trials: with existing treatment
options as comparator larger trials compensating for overall low
event rates are necessary. Trials will become far more expensive
and difficult to conduct. The reason, why placebo groups of recent
trials show a less active disease course, is unclear.
A meta-analysis of demographic data and key points of study
protocols as predictors for relapse rates during the last 20 years
appears feasible.
In 2005, when reduction of relapse rates over time was not yet
under discussion, Held et al. [5] used multiple regression models to
identify predictors of the ARR. Data for this study were obtained
from the Sylvia Lawry Centre for MS Research (SLC) individual
case data base consisting of data from several placebo cohorts of
phase-2 and 3 studies. The ARR of placebo patients in RCTs up
to the year 1999 correlated well with the pre-study relapse rate and
inversely with the disease duration at baseline. A possible change
of the behaviour of placebo cohorts over time was not assessed by
this approach. MRI variables at baseline did not show an
additional predictive value on relapse and disability outcomes in
RRMS populations. [6,7] Inusah et al. were the first to analyse the
reduction of the ARR over time (1981 till 2008) in placebo groups
of phase-2 and 3 trials by univariate and multivariate regression
analysis in 2010. They found a predictive value of lower baseline
mean age and of the definition of relapses either with a minimal
duration of 24 or 48 hours for higher ARR on study. [8] Their
analysis was limited in including only ARR as disease activity
criterion in the multivariate regression. Furthermore, they
analysed RRMS as well as secondary-progressive MS (SPMS)
cohorts in a heterogenous mixture of phase-2 and 3 studies,
whereas recent large phase-3 trials were not included.
To the best of our knowledge, the phase-3 studies published till
2012 have not been included in a meta-analysis yet. Furthermore,
a random-effects meta-regression has never been performed in this
dataset. Random-effects meta-regression is recommended and
widely used to analyse the heterogeneity of studies in a meta-
analysis. [9–11] Heterogeneity derives from different trial designs
or different demographic characteristics of study populations. As
the variance of the ARR may reflect heterogeneity of studies, the
above mentioned meta-regression methodology seems the most
appropriate statistical method to evaluate different variables as
possible moderators of this heterogeneity [9].
Based on this concept, we aimed at covering the widest possible
time-frame of high quality phase-3 trials in RRMS to asses 1.) The
predictive value of baseline demographic factors and 2.) The
impact of the McDonald criteria (2001, revised 2005) for clinical
disease activity.[12,13] This is especially relevant as the actual
revision of McDonald criteria has just been published allowing a
MS diagnosis at the time of first symptoms. [14] By use of the SLC
database, we wanted to 3.) test possible predictors from the meta-
analysis based on individual case data.
Methods
Our statistical analysis plan was designed to combine three
possible ways of analysing predictors for relapse outcomes of
randomized placebo controlled phase-3 clinical trials of relapsing-
remitting MS: The results of (1) univariate and multivariate
regression analyses and (2) a random-effects meta-analysis were
compared. Additionally, we (3) evaluated cases in the open part of
the SLC database. Exclusion of CIS, SPMS and primary-
progressive MS (PPMS) patients seemed reasonable to avoid a
bias towards MS courses with lower relapse activity. Phase-2
studies were not included in the analysis for the following reasons:
relapses are not the usual primary outcome in MS phase-2 trials
and there are no available data on relapse-free patients from most
of these studies. Finally short durations between 6 and 12 months
make estimates of the ARR less reliable. The ARR and the rate of
relapse-free patients after 2 years (RRF) within the placebo
cohorts were focussed as outcomes of interest. Based on the
difficulties of relapse diagnosis and the on-going debate on the
relevance of relapse numbers for prognosis the free-of-relapse
criterion seems the more robust relapse outcome as it less
influenced by number of relapses per patient and simply
differentiates between missing or on-going relapse activity.
SLC has been collecting anonymised data from various data
donors of natural history studies and randomized controlled
clinical trials. The data it selves have been collected by the data
donors with appropriate consent forms. Without explicit permis-
sion of the data donor even the data donor is anonymised.
Selection of studies
At first, a comprehensive literature research within the Pubmed
database was performed (last access in March 2012) by one
reviewer (JPS) with the following keywords: ‘randomized placebo
controlled trial in relapsing remitting multiple sclerosis’. The
results of the electronic search (n= 253) was screened by headers
and abstracts if available. Only full-length original English journal
publications were reviewed to identify studies that met the
following criteria (n = 11): (1) placebo-controlled double-blinded
phase-3 trials in MS with a follow up of at least 18 months, (2)
relapse related outcomes, (3) exclusion of SPMS, PPMS and CIS
patients and (4) published between 1980 and March 2012. Record
selection, exclusions and inclusion of studies according to the
PRISMA guidelines are presented in figure 1.[15] JPS and CH.
performed exclusions.
Data extraction
From of the publications following data was extracted: the name
of the first author, year of publication and number of patients in
the placebo cohort; the trial start date, the ARR and the RRF; the
baseline characteristics of these cohorts including mean age, mean
disease duration, rate of females, mean pre-study relapse rate and
mean EDSS; definition of disease duration (time since first
symptoms or time since diagnosis), relapse definition (24 or
48 hours of minimal symptom duration) and whether the
McDonald criteria were applied. Throughout this paper the
ARR and the RRF are labelled as ‘‘outcomes’’ while trial start
dates, baseline values and definitions are mentioned as variables.
For all means the standard deviations (SD) were also extracted if
published. Available confidence intervals or standard errors were
converted to SD. Missing values and definitions were obtained
from data on file by contacting authors and sponsors of the
publications and trials. To avoid data copying mistakes, the final
dataset was reviewed by two collaborators (JPS and SR).
Statistical methods
Standard errors (SE) for the rate of relapse free patients were
calculated as proposed by Gelmann and Hill.[16] Missing SD of
ARR means were estimated under the assumption, that relapses
Predictors for On-Trial Disease Activity in MS
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follow a Poisson distribution. For all continuous variables a
descriptive analysis with median, range, mean and SD was
conducted. Scatter plots and regression analyses were used to
determine if ARR and RRF did show a significant change over
time defined by the trial start dates. Adjusted coefficients of
determination (adjR2) between ARR/RRF and baseline values as
well as between trial start date and baseline values were calculated.
Besides these univariate models, multivariate regression models
were applied as well. The included variables were selected by
stepwise backward selection on base of the Akaike information
criterion (AIC) that indicates the relative goodness of fit.[5,17] All
regression models were weighted for the number of patients.
Within random-effect meta-analyses the observed outcomes are
understood as a random selection of the normally distributed
outcomes.[18] Different designs and populations of these studies
lead to an additional heterogeneity or variability of the true
outcome. This can be taken into account by adding a random
effect allowing an estimation of the heterogeneity with tau2 as the
between-study variance. Within mixed effect models, variables
may be added and analysed in their ability in reducing the
heterogeneity of the pure random effects model.[18,19] The
reduction of tau2 indicates the association between outcome and
variables.
Within our analysis we calculated I2 (proportion of heteroge-
neity among true effects of total variability) and tau2 (between
study variance) for the pure random effects models. A detection of
outliers was implemented. For the mixed-effect models we
included each variable separately and calculated tau2 and its
relative change compared to the pure random effect model as a
measure of association between variable and outcome.[18] Finally,
we modelled a mixed-effects analysis with the two variables which
reduced the heterogeneity most effectively as recommended by
Houwelingen et al.[19].
Figure 1. Flow chart: Study selection for meta-analyses. According to the PRISMA guidelines. [15].
doi:10.1371/journal.pone.0050347.g001
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Besides descriptive statistics of the pooled placebo population of
the SLC database (open part), Poisson regression models were
used to examine the correlation of possible predictors with the
ARR. Logistic regressions were calculated for the models
concerning the outcome relapse free after 2 years. Date of study
entry was used equivalent to the trial start date. To ensure the
blinding of the SLC database and to avoid conclusions about a
single study, date of study entry was constructed as ordinal
variable with each rank including at least two studies. Other
variables were selected according to the meta-regression analyses.
The final multivariate models based on variable selection by AIC.
All analyses were performed with the open-source software R
including the Hmisc and the metafor package.[18,20,21] The
results of the random-/ mixed effect meta-analyses were revised
with STATAH.
Results
Datasets
We identified 11 published trials [1–4,22–28] that met our
inclusion criteria. One further placebo cohort from an unpub-
lished trial (ORIGIMS – A randomised, parallel group, placebo-
controlled, double-blind phase-3 study of BioferonH (interferon
beta-1a) in the treatment of relapsing-remitting multiple sclerosis)
could be added to the simple and meta-regression analyses from
the SLC database, since the study sponsor had given its explicit
consent to allow a separated re-analysis of the placebo cohort data.
A dataset from a 13th study could be added based on 2011
conference proceedings.[29,30] The available data is presented in
table 1. For all trials we could determine the RRF and calculate
the corresponding SE. The ARR with corresponding SD was
available from all studies except three. 9 Studies used the time
since diagnosis as definition for the baseline disease duration while
4 trials used the time since first symptoms. These were labelled as
missing for the analysis. All trials conducted before 2001 (n= 6)
included only clinically definite MS-cases while the 7 most recent
trials implemented the McDonald criteria (6 studies with the 2001
criteria, 1 study with the revised criteria from 2005). This dataset
was used for the simple regression and the random-effects meta-
regression. The SLC dataset of individual case data consisted of a
pool of 505 placebo patients. The two datasets overlapped
concerning pivotal trials from the 1990ies, the ORIGIMS data
was only included in the first dataset and excluded from the
individual case data due to blinding reasons. Individual case data
from more recent trials was not available due to restrictive data
sharing policies of the involved companies. Therefore, findings
from the meta-regression could not be confirmed in a comparable
individual case dataset.
Univariate and multivariate regression
There was a significant reduction of the ARR over time
(adjR2= 0.807, p,0.0001, Figure 2) while, inversely, the RRF
increased (adjR2 = 0.728, p = 0.0001, Figure 3) with a high
association between both outcome measures (adjR2 = 0.815,
p,0.0001). In the subgroup of studies not using McDonald
criteria, i.e. before 2001, change over time was not significant.
Univariate regression models showed a correlation of lower ARR
and higher RRF with higher age, lower pre-study relapse rate and
the use of the McDonald criteria. Definition of relapse duration
was not significantly associated with the ARR but tended to show
more relapses in the subgroup of studies using 48 hours as minimal
relapse duration (data not shown). Further on, baseline mean age
increased significantly over time while the pre-study relapse rate
decreased significantly (Table 2 and Figure 4). By stepwise reverse
exclusion of variables based on AIC we finally modelled a
multivariate regression with baseline mean age and trial start dates
as best predictors for the ARR (adjR2= 0.821, p,0.0001). The
RRF was best predicted by McDonald criteria and baseline mean
age (adjR2 = 0.831, p,0.0001).
Random-effect meta-regression
In a second step we performed the random-effect meta-analysis.
Models without predictive variables showed that the variance of
outcomes alone could not explain the between-study variability.
For ARR we calculated as follows: I2 = 98.9% (CI 97.8–99.7%) of
total variability due to heterogeneity (tau2 = 0.16, p,0.0001). The
corresponding value for the RRF was I2 = 97.4% (CI 95.0–99.1%,
tau2 = 0.03, p,0.0001). No outliers could be detected by the
‘‘leave one out’’ method. Using start dates, baseline variables as
well as the categorical definitions as single variables in each mixed-
effect model for ARR and RRF, we found trial start dates, baseline
mean age, rate of females, pre-study relapse rate and the use of
McDonald criteria associated with both outcomes. Other variables
failed to reduce tau2 significantly showing that there is no
association with the outcomes in our analyses. Baseline mean
EDSS, the definition of relapses and definition of disease duration
even increased tau2 in some models. Results of all models
calculated and the association of variables with outcomes,
measured by their ability in reducing tau2, are presented in
table 3. Models with two variables did not show a significant
higher association with relapse outcomes than the model with the
best single predictor, which were trial start dates for both outcomes
ARR and RRF.
SLC database
In the third step of our analysis plan the regression models were
evaluated based on 505 pooled placebo patients of the SLC
database with a follow-up of at least 2 years. Due to blinding
reasons data from patients entering the trials after 1999 could not
be included. Descriptive statistics are presented in table 4 and did
not show obvious deviation from other RRMS populations. The
list of variables included in the multivariate models was reduced
compared to the models applied to the cohorts from the literature
for the following reasons: (1) definition of relapse was not available;
(2) definition of disease duration was always the same (since
diagnosis) and (3) McDonald criteria could not be analysed as all
patients had clinically definite MS. Within the Poisson regression
model the pre-study relapse rate in the year before entry
(coefficient estimate = 0.12, p,0.001) could be identified as
significant and best predictor of the ARR besides the date of entry
in trial by year (coefficient estimate = 20.05, p,0.001).
Analysing the RRF lead to the same results and showed an
interestingly rapid decrease in the risk of relapses in studies after
1994 as indicated by the coefficients (Table 5). Baseline disease
duration, age and gender had no further predictive value within
multivariate models.
Discussion
Our results of the yet largest meta-analysis of placebo cohorts in
MS phase-3 trials confirm the notion of a reduction of relapse rates
from 1990 to 2012 published studies. Individual data models from
the SLC database between 1980 and 1999 also supported those
findings. The most reliable meta-analytic results can be achieved
by the analysis of pooled individual patient data as simulation
studies indicated.[9] Interestingly our re-evaluation of the SLC
data including the moderator ‘‘entry to trial date’’ lead to a final
multivariate regression model without the pre-study disease
Predictors for On-Trial Disease Activity in MS
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Figure 2. Change of annualized relapse rates of MS phase-3 placebo cohorts over time. n=13. Circle size corresponds to weighting by
patient numbers of each cohort. R2 is the proportion of variability in the data that is accounted for by the weighted univariate regression model.
doi:10.1371/journal.pone.0050347.g002
Figure 3. Change of the relapse free patients rate of MS phase-3 placebo cohorts over time. N=13. Circle size corresponds to weighting
by patient numbers of each cohort. R2 is the proportion of variability in the data that is accounted for by the weighted univariate regression model.
doi:10.1371/journal.pone.0050347.g003
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Figure 4. Change of mean age and pre-study relapse rates of MS phase-3 placebo cohorts over time. N=13. Circle size corresponds to
weighting by patient numbers of each cohort. R2 is the proportion of variability in the data that is accounted for by the weighted univariate
regression model.
doi:10.1371/journal.pone.0050347.g004
Table 2. Predictors for relapses - coefficient of determination in weighted regression models.
ARR RRF Start Date
Coefficient
estimate adjusted r2
Coefficient
estimate adjusted r2
Coefficient
estimate adjusted r2
Baseline
Variables
Mean age 20.20 (*) 0.612 0.09 (*) 0.693 0.01 (*) 0.554
Rate females 3.22 0.098 21.52 0.143 0.01 0.034
Mean disease duration 20.11 0.117 0.05 0.096 0.01 -0.041
Pre-study mean relapse
rate
0.38 (*) 0.504 20.17(*) 0.557 20.01 (*) 0.503
Mean EDSS 20.15 0.010 0.16 20.014 0.01 20.014
Definitions Disease duration 0.29 0.131 20.05 20.050
Minimal relapse duration 20.01 20.072 20.01 20.097
McDonald criteria used 20.70(*) 0.744 0.30(*) 0.762
Coefficient estimates and coefficient of determination (adjusted R2) of univariate regression models of baseline variables and outcomes. R2 is the proportion of
variability in the data that is accounted for by univariate regression model. Variables were also analysed for their change over time (variables vs. start date). Significant
(p,0.05 (*)) correlations were used for the multivariate modelling. RRF = Rate of relapse free patients after 2 years, ARR = Annualized relapse rate over 2 years.
doi:10.1371/journal.pone.0050347.t002
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duration as independent predictor. This extended the analysis of
Held et al. from 2005 whose analysis did not consider ‘‘entry to
trial date’’ and whose final model included the pre-study relapse
rate and the pre-study disease duration.[5] In fact, the actual
analysis demonstrates that the date of study entry has a higher
predictive value for on-study relapse rates than the pre-study
disease duration.
Mixed-effect models applied on the 12 placebo cohorts from the
literature and the 13th study from the SLC database suggested the
McDonald criteria, baseline mean age and pre-study relapse rate
as well as the rate of females as predictors for the on-study relapse
activity. These models are more robust than simple regressions as
mixed-effects models take unavoidable differences between the
included trials into account.[10,11] In our study, the congruence
between the analysis of both relapse outcomes was higher in the
mixed-effect models than in simple regression models.
The mixed-effect models showed a clear association between
less relapses and the inauguration of the McDonald criteria that
could be shown for the first time in a meta-analytic approach.
Unfortunately, we could not test this finding on an individual case
data base. To ensure blinding of individual placebo cohorts of
RCTs only studies before 2000 could be considered in this
analysis. This led to a data pool lacking RRMS cohorts diagnosed
with McDonald criteria and a discrepancy between the study
populations used for the meta-regression and the individual case
data analyses. In how far the observed effects are based mainly on
the fact that the use of McDonald criteria might be understood as
a categorical time variable differentiating between older and
younger studies, cannot be clarified based on the available data.
Start dates and the use of McDonald criteria showed nearly the
same predictive value in classic and random-effect regression
models. Models with both variables did not further increase the
predictive value of the univariate models. All other variables failed
to neutralize these high correlations. A differentiation between a
continuous or stepwise decrease of the ARR cannot be performed
with the available data and prohibits estimating the ARR for
future trials.
The correlation between new diagnostic criteria and disease
activity refers to two major problems. First, defining more and
more patients with a chronic-inflammatory but benign condition
as MS patients leads to a further reduction of relapse rates in the
continuously expanding MS population. This phenomenon was
described by Sormani et al. as Will Rogers phenomenon in an
cohort of 309 CIS patients in 2008.[31] The increasingly
diagnosed so-called ‘radiological isolated syndrome’ (RIS) high-
lights this problem as real relapse activity is already known to be
rare in this group. Within an US RIS cohort of 41 MS-symptom-
free patients with a MRI suggestive of MS only 59% showed MRI
activity and only 10 patients (25%) developed at least a clinically
isolated syndrome (CIS) after a median of 5.4 years.[32] Secondly,
results from treatment studies and prognostic factors within
natural cohorts from the pre-McDonald era cannot be transferred
to contemporary MS-cohorts. Therefore it is more pressing to find
new prognostic criteria for disability than more sensitive, sub-
clinical diagnostic criteria. Expanding the MS population towards
RIS with more sensitive diagnostic criteria disseminates the MS
stigma with a vague benefit for patients and physicians being
highly ambivalent to recommend treatments at this stage.
The pre-study relapse rate was less predictive than McDonald
criteria in the mixed-effect models. This may at least partially be
affected by recruitment strategies between older and newer studies:
In consequence of accepting uncertain or unspecific symptoms in
the disease history to fulfil a required number of relapses for study
inclusion the true pre-study relapse rate may be overestimated in
the newer studies. Probably a stricter definition of pre-study
relapses e.g. steroid treatment, documented motor, visual or
Table 4. Descriptive statistics of the individual patient cohort
(SLC database).
N=505 Mean (SD) N (%) Median Range
Gender (female) 366 (72.5%) - -
Baseline disease duration
in years
7.2 (6.1) 5.5 0.3–37.7
Baseline Age 35.6 (8.1) 36 17–62
Pre-study ARR last 12
month
1.4 (1.0) 1 0–6
Pre-study ARR last 24
month
3.0 (1.6) 3 0–12
SD = Standard deviation.
doi:10.1371/journal.pone.0050347.t004
Table 5. Individual patient cohort – final Poisson and logistic regression models.
N=505 Outcomes
ARR Relapse free after 2 years
Regression Model Poisson Logistic (trial entry date as categorical variable)
Coefficient P value categories coefficients P value
Variables Trial entry date 20.05 0.02 1991–93 20.03 0.9
1994 0.13 0.8
1995 21.05 0.02
1996 22.67 ,0.0001
1997 21.04 0.01
1999 21.39 0.04
Pre-study relapse
rate (last year)
0.12 ,0.0001 0.16 0.04
ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at least 1 relapse in 2 years or 0 for no relapse in 2 years, reference
category for trial entry was 1990 or earlier.
doi:10.1371/journal.pone.0050347.t005
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brainstem symptoms might be useful to have a more robust
estimate for historical relapse frequencies.
Besides the relevance of pre-study relapses, McDonald criteria
and trial start dates in our mixed-effect models give additional
statistically reliable and clinically meaningful results: Young female
patients have a higher short-term risk for further relapses.
The correlation of age and on-study relapses within the
literature cohorts confirm the analysis of Inusah et al. but stays
in contrast to the SLC data, where age did not increase the
predictive value of multivariate models including pre-study
relapses and year of study entry. This finding might be affected
by the lower mean age of the SLC patients. As in the case of
McDonald criteria, the restricted availability of individual case
data denied a clarification of this discrepancy. Possible explana-
tions might be higher sensitivity of McDonald criteria in older
patients with lower relapse activity or previous treatment with
approved drugs. In addition, the availability of approved therapies
since 1993 may have lead to a selection towards older and less
active patients for studies. This might be as well the reason for the
nearly stepwise decrease of the relapse risk after 1994 observed
within the logistic regression of the individual case data. Future
cohorts with younger patients might help to clarify the relevance of
age and disease duration for onstudy disease activity. The finding
by Inusah et al., that different definition of relapses by minimal
duration (24 or 48 hours) influences the ARR, could not be
confirmed by our data. A small effect may be missed by our
reduced data set, as only 4 studies used the 48 hours definition. [8]
But, as our data even show a tendency towards more relapses in
the subgroup with the more rigorous definition, we do not identify
real implications for future trial design in this.
According to our findings future RRMS trials need a careful
definition of inclusion criteria and novel trial designs have to be
discussed as solution for an unpredictable ARR. Recently,
Nicholas et al. published simulation studies that proposed adaptive
designs to control sample sizes and power.[33].
Meta-analyses are always restricted by the available studies.
Only 12 phase-3 RCTs in RRMS with a follow-up of at least 18
months have been published in the last 20 years. Negative MS
trials showing no effect of an investigational drug are difficult to
retrieve. In fact, low event rates in placebo groups might be a
major reason for not showing treatment effects. This was the case
of the ORIGIMS trial, which we could include in our analysis. As
our systematic literature research did not reveal one single
negative trial, a substantial publication bias must be stated.
Therefore our data set probably even overestimates the true ARR.
The low number of studies restricted our mixed-effect models to a
maximum of two moderators per model and inhibited a direct and
statistically meaningful comparison of different moderators. Due
to missing data the MRI criteria and prior treatments could not be
included in our analyses but might have impacted on the disease
activity and therefore relapse rates as well.
Conclusions
Up to now all analysed predictors failed to satisfactorily explain
the lowering of relapse rates in phase-3 trials over the last decades.
Inclusion criteria for future phase-3 trials in RRMS with relapse-
based outcomes should be adjusted based on the results of our
analysis showing that higher age and lower pre-study relapse rates
are associated with a lower on-study ARR. The relevance of prior
disease modifying treatments, the change of relapse rates over time
and even more important the effect of new diagnostic criteria must
be further analysed on an individual case data base. We emphasize
the importance to continue gathering and sharing the data of
placebo cohorts – and treatment data – as it has been started in the
SLC in 2001.
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